Futu News on July 8 news, the new shares rose again the day after Ju Ophthalmology listed. As of press time, Chaoju ophthalmology is up 19.15% to HK $16.80, up nearly 60% from IPO's price of HK $10.60, with a turnover of HK $499 million.

It is reported that Chaoju Ophthalmology is a leading ophthalmic medical service group in North China, founded in 1988, and has established an extensive network of ophthalmic hospitals and optometry centers, spanning Inner Mongolia, Zhejiang Province, Jiangsu Province, Shanxi Province and Hebei Province. As of the latest practicable date, the company operates a total of 17 eye hospitals, 23 optometry centres and 2 clinics.

According to Frost Sullivan's report, among private eye hospitals, Chaoju ophthalmology ranks first in Inner Mongolia, second in North China and fifth in China in terms of total revenue in 2020.

In terms of industry, China has a huge and fast-growing market for ophthalmic medical services. The size of China's ophthalmic medical service market has increased from 73 billion yuan in 2015 to 127.5 billion yuan in 2019, with a compound annual growth rate of 15 percent, and is expected to reach 223.1 billion yuan in 2024.

As of press time, Citic Lyon ranked first in net buying of broker seats, with a net purchase of 3.7916 million shares; J.P. JPMorgan ranked second in net buying of broker seats, with a net purchase of 1.7889 million shares, while Citic ranked third in net buying of brokerage seats, with a net purchase of 1.0298 million shares.